Flavivaccine presents an innovative and safer strategy with the potential to broaden the scope of vaccine effectiveness. This preventative strategy is designed to reduce hospitalisations and burden to healthcare by providing a prophylactic solution against multiple diseases.

The consolidation of efforts into a single vaccine streamlines resource allocation and eases the strain on healthcare systems. Therefore, beyond public health, the project has the potential to help reduce the economic cost associated with global mosquito-borne diseases (€9 billion per year) and reduce its social burden, by protecting communities and citizens globally.

By managing the entire research and development process, the project also aims to provide a platform to enhance the EU’s preparedness and response to future epidemic or pandemic threats.

Taken together, within Flavivaccine, we will identify common targets to all flaviviruses that are safe, immunogenic and provide protection against these viruses. By the end of the project, we aim to have a vaccine candidate ready to enter clinical development.